Chronic lymphocytic leukaemia+1
Not yet recruitingSafety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia
Safety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia
- Disease:Chronic lymphocytic leukaemiaChronic lymphocytic leukaemia recurrent
- Substances:DaratumumabObinutuzumab+1
Poland- Participants:18–64 years · 65+ years
- Substances:Daratumumab
- Sponsor:Uniwersytet Medyczny W Lublinie












